Select a medication above to begin.
Vyxeos
daunorubicin/ cytarabine liposomal
Black Box Warnings .
Non-Interchangeable Forms
do not interchange w/ other daunorubicin- and/or cytarabine-containing products, incl. daunorubicin, cytarabine, daunorubicin liposomal, and cytarabine liposomal, as dosage recommendations differ; verify drug name and dose prior to use to avoid dosing errors
Adult Dosing .
Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: not interchangeable w/ other daunorubicin- and/or cytarabine-containing products; combo liposomal product contains daunorubicin + cytarabine at fixed 1:5 molar ratio
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
AML
- [induction tx]
- Dose: daunorubicin liposomal 44 mg/m^2/dose + cytarabine liposomal 100 mg/m^2/dose IV x1 on days 1, 3, 5 of cycle; Max: cumulative daunorubicin dose 550 mg/m^2 or 400 mg/m^2 if prior mediastinal XRT; Info: for newly diagnosed therapy- or myelodysplasia-related AML; if remission not achieved, may give x1 additional cycle daunorubicin liposomal 44 mg/m^2/dose + cytarabine liposomal 100 mg/m^2/dose IV x1 on days 1, 3 of cycle, starting 2-5wk after induction tx
- [consolidation tx]
- Dose: daunorubicin liposomal 29 mg/m^2/dose + cytarabine liposomal 65 mg/m^2/dose IV x1 on days 1, 3 of 35- to 56-day cycle; Start: 5-8wk after start of last induction tx; Max: cumulative daunorubicin dose 550 mg/m^2 or 400 mg/m^2 if prior mediastinal XRT; Info: for newly diagnosed therapy- or myelodysplasia-related AML; give up to 2 cycles
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin <3: no adjustment; bilirubin >3: not defined
Peds Dosing .
- Dosage forms: INJ
Special Note
- [formulation clarification]
- Info: not interchangeable w/ other daunorubicin- and/or cytarabine-containing products; combo liposomal product contains daunorubicin + cytarabine at fixed 1:5 molar ratio
- [uses, dosing may vary]
- Info: refer to institution protocols and pkg insert prior to prescribing for uses and dosing incl. toxicity-related dose adjustments
AML
- [induction tx, 1 yo and older]
- Dose: daunorubicin liposomal 44 mg/m^2/dose + cytarabine liposomal 100 mg/m^2/dose IV x1 on days 1, 3, 5 of cycle; Max: cumulative daunorubicin dose 550 mg/m^2 or 400 mg/m^2 if prior mediastinal XRT; Info: for newly diagnosed therapy- or myelodysplasia-related AML; if remission not achieved, may give x1 additional cycle daunorubicin liposomal 44 mg/m^2/dose + cytarabine liposomal 100 mg/m^2/dose IV x1 on days 1, 3 of cycle, starting 2-5wk after induction tx
- [consolidation tx, 1 yo and older]
- Dose: daunorubicin liposomal 29 mg/m^2/dose + cytarabine liposomal 65 mg/m^2/dose IV x1 on days 1, 3 of 35- to 56-day cycle; Start: 5-8wk after start of last induction tx; Max: cumulative daunorubicin dose 550 mg/m^2 or 400 mg/m^2 if prior mediastinal XRT; Info: for newly diagnosed therapy- or myelodysplasia-related AML; give up to 2 cycles
renal dosing
- [see below]
- CrCl >15: no adjustment; CrCl <15: not defined
- HD/PD: not defined
hepatic dosing
- [see below]
- bilirubin <3: no adjustment; bilirubin >3: not defined